Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA)
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216275%3A25310%2F15%3A39900618" target="_blank" >RIV/00216275:25310/15:39900618 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11160/15:10312611 RIV/62157124:16170/15:43873571 RIV/62157124:16370/15:43873571 RIV/62157124:16810/15:43873571
Result on the web
<a href="http://dx.doi.org/10.1016/j.ejps.2015.06.009" target="_blank" >http://dx.doi.org/10.1016/j.ejps.2015.06.009</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejps.2015.06.009" target="_blank" >10.1016/j.ejps.2015.06.009</a>
Alternative languages
Result language
angličtina
Original language name
Salicylanilide carbamates: Promising antibacterial agents with high in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA)
Original language description
A series of twenty-one salicylanilide N-alkylcarbamates was assessed for novel antibacterial characteristics against three clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) and S. aureus ATCC 29213 as the reference and quality control strain. The minimum inhibitory concentration was determined by the broth dilution micro-method with subsequent subcultivation of aliquots to assess minimum bactericidal concentration. The bactericidal kinetics was established by time-kill assay. Ampicillin, ciprofloxacin and vancomycin were used as reference antibacterial drugs. All the tested compounds exhibited highly potent anti-MRSA activity ({= 0.008-4 mu g/mL) comparable or up to 250x higher than that of vancomycin, the standard in the treatment of serious MRSA infections. 4-Chloro-2-(3,4-di chlorophenylcarbamoyl)phenyl butylcarbamate and 4-chloro-2-(3,4-dichlorophenylcarbamoyl)phenyl ethylcarbamate were the most active compounds. In most cases, compounds provided reliable bacteriostatic activity, except for 4-chloro-2-(4-chlorophenylcarbamoyl)phenyl decylcarbamate exhibiting bactericidal effect at 8 h (for clinical isolate of MRSA 63718) and at 24 h (for clinical isolates of MRSA SA 630 and MRSA SA 3202) at 4x MIC. Structure-activity relationships are discussed.
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FR - Pharmacology and apothecary chemistry
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: Central european institute of technology</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Pharmaceutical Sciences
ISSN
0928-0987
e-ISSN
—
Volume of the periodical
77
Issue of the periodical within the volume
September 2015
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
11
Pages from-to
197-207
UT code for WoS article
000358975600022
EID of the result in the Scopus database
—